Page 38 - Alimera Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share:   Amid required stay-at-home orders, many have paused or canceled doctor’s appointments over the past 12 months. Recent studies show some of the troubling effects of patients missing out on treatments for vision loss. Alimera Sciences believes it has a solution.  A Daily Microdose Recently, the Cleveland Clinic published a paper, “The Effect of Delay in Care Among Patients Requiring Intravitreal Injections,” regarding the results of patients missing their prescribed vision loss treatments due to the COVID pandemic.  This 1,041-patient retrospective analysis examined the effect...

Search jobs 20-Apr-2021 Ocular Drug Delivery System Market Analysis and In-depth study on Market Size Trends, Emerging Growth Factors and Regional Forecast to 2027 | FMI Ocular drug delivery system designed to treat eye locally, whereas the conventional method of drug delivery is less effective due to the presence of various barriers. The bioavailability of the active drug substance is sufficient in ocular drug delivery system to combat an ocular disease. Various technology and method used in ocular drug delivery systems such as intravitreal injec...

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland March 17, 2021 08:00 ET | Source: Alimera Sciences, Inc. Alimera Sciences, Inc. Alpharetta, Georgia, UNITED STATES ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces continued execution on its ...

Corporate Highlights Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an all-time high of $206.0 million, accompanied by strong credit trends Closed a $9.0 million transaction in March 2021, deploying $7.1 million Received two milestone payments from Cara Therapeutics totaling $5.0 million, with SWK retaining $3.0 million and the other $2.0 million being remitted to Enteris' prior owner.  Specialty Finance Segment Highlights: For the fourth quarter of 2020, finance por...

Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland March 17, 2021 08:00 ET | Source: Alimera Sciences, Inc. Alimera Sciences, Inc. Alpharetta, Georgia, UNITED STATES ATLANTA, March 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces continued execution on its ...